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ABSTRACT
Androgen receptor (AR) is a ligand-activated tran-
scription factor that plays a central role in the de-
velopment and growth of prostate carcinoma. PIAS1
is an AR- and SUMO-interacting protein and a pu-
tative transcriptional coregulator overexpressed in
prostate cancer. To study the importance of PIAS1
for the androgen-regulated transcriptome of VCaP
prostate cancer cells, we silenced its expression by
RNAi. Transcriptome analyses revealed that a sub-
set of the AR-regulated genes is significantly influ-
enced, either activated or repressed, by PIAS1 de-
pletion. Interestingly, PIAS1 depletion also exposed
a new set of genes to androgen regulation, suggest-
ing that PIAS1 can mask distinct genomic loci from
AR access. In keeping with gene expression data,
silencing of PIAS1 attenuated VCaP cell prolifera-
tion. ChIP-seq analyses showed that PIAS1 interacts
with AR at chromatin sites harboring also SUMO2/3
and surrounded by H3K4me2; androgen exposure in-
creased the number of PIAS1-occupying sites, result-
ing in nearly complete overlap with AR chromatin
binding events. PIAS1 interacted also with the pio-
neer factor FOXA1. Of note, PIAS1 depletion affected
AR chromatin occupancy at binding sites enriched
for HOXD13 and GATA motifs. Taken together, PIAS1
is a genuine chromatin-bound AR coregulator that
functions in a target gene selective fashion to regu-
late prostate cancer cell growth.
INTRODUCTION
Androgen receptor (AR) acts as a hormone-controlled tran-
scription factor that conveys the messages of both natural
and synthetic androgens to the level of genome (1,2). In
prostate,AR is needed as a differentiation factor for the nor-
mal development, function and maintenance of the gland.
AR also plays a critical role in the pathogenesis of prostate
cancer, the most commonly diagnosed cancer among West-
ern men (3). Proliferation of cancerous prostate cells can
initially be inhibited by androgen ablation. However, for
reasons that are currently unclear, this therapy eventually
fails leading to castration resistant prostate cancer (CRPC).
The CRPC has been proposed to result from e.g. mutations
in AR, AR variants, augmented expression of AR or its
coregulator proteins, aberrant AR posttranslational modi-
fications, gene fusions resulting in abnormal androgen regu-
lation of oncogenic transcription factors and intracrine an-
drogen production (4–6).
Binding of androgen to the AR monomer in the cy-
toplasm causes a conformational change in the recep-
tor’s ligand-binding domain (LBD), leading to dimeriza-
tion and nuclear translocation of the AR. The dimeric AR
binds to specific DNA elements, androgen response ele-
ments (AREs), resembling the sequence AGAACAnnnT-
GTTCT (n is any nucleotide) (2). According to recent
genome-wide chromatin immunoprecipitation (ChIP-seq)
analyses, the majority of genomic AR-binding sites con-
tain at least one TGTTCT half-site flanked with a less well-
conserved 3′ hexamer (7–10). In addition to the ARE it-
self, adjacent binding sites for other transcription factors
seem to play an important role in the DNA binding, often
governing the AR binding. These ‘AR-collaborating’ fac-
tors that often bind to sites in close proximity to AREs
include GATA-binding protein 2 (GATA2), E twenty-six
or E26 transformation-specific (ETS) transcription factors
and pioneer factor forkhead box A1 (FOXA1) (7,11–14). In
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addition to facilitating AR binding to chromatin, FOXA1
can also mask chromatin binding sites of the receptor (7).
However, the mechanisms underlying differential FOXA1
and subsequently AR binding are currently not known. In
addition to the general transcription machinery and RNA
polymerase II, AR requires a number of interacting coreg-
ulator proteins to regulate transcription. A large number,
over 200 AR-interacting proteins have been reported to
potentially influence the receptor’s transcriptional activ-
ity (1,15). These include SWI/SNF chromatin-remodeling
complexes, together with steroid receptor coactivators and
corepressors that harbor or recruit enzymatic activities that
catalyze histone acetylation or methylation and/or removal
of these post-translational modifications (16). Some puta-
tive coregulators also promote ubiquitylation or SUMO
(small ubiquitin-related modifier) modifications (SUMOy-
lation) which all can also target nucleosomal histones and
AR (1,17). Cell- and tissue-specific differences in the expres-
sion patterns of AR coregulators and collaborating tran-
scription factors are thought to contribute significantly to
the differences in AR target gene activities between differ-
ent tissues (1). However, the physiological importance and
functional relevance of the majority of potential AR coreg-
ulators have remained elusive, as they have in most cases
been tested merely under ectopic overexpression conditions
in reporter gene assays.
Protein inhibitor of activated STAT (PIAS) 1 is a can-
didate AR coregulator, as it interacts with AR and in-
fluences its activity in transactivation assays (18–20). Al-
though PIAS1, like the other PIAS family proteins PIAS2
(x), PIAS3, PIAS4 (y), has the capacity to catalyze SUMOy-
lation of interacting proteins, including AR, the SUMO
ligase activity is not its sole function as is the case also
with the other PIAS proteins (21,22). Of note, expression
of PIAS1 protein is significantly elevated in malignant ar-
eas of prostate cancer compared to normal tissue, suggest-
ing a pathophysiological role in prostate cancer cell growth
(23,24). However, there is no information on the role of
PIAS1 in the regulation of endogenous AR target genes
in prostate cancer cells. In this study, we have used VCaP
(Vertebral-Cancer of the Prostate) cells that are derived
from a CRPC (25) to analyze the role of endogenous PIAS1
in the regulation of AR target genes in a genuine chromatin
environment. The cell line contains amplified levels of AR,
it is androgen sensitive and tumorigenic and it expresses
enzymes involved in intratumoral androgen biosynthesis
whose expression is induced in VCaP xenografts grown in
castrated mice (26). It is thus an attractive in vitro model for
CRPC. Our genome-wide approaches revealed that PIAS1
acts as a chromatin-bound AR coregulator that also inter-
acts with FOXA1 and functions in a selective fashion in AR
target gene expression. Expression of several genes was sig-
nificantly affected, either activated or repressed by PIAS1,
and these genes were associated with cellular growth and
proliferation, gene expression and protein synthesis func-
tions.
MATERIALS AND METHODS
Cell culture and hormones
VCaP cells was obtained from American Type Culture Col-
lection (ATCC) and maintained as previously described
(27). R1881 (methyltrienolone) and testosterone were from
Steraloids Inc.
RNA interference
VCaP cells were seeded onto 12-well plates for RNA isola-
tion (270 000 cells/well) and for proliferation assays onto
six-well plates (500 000 cells/well) for 2 days before trans-
fection. The transfection medium DMEM containing 2.5%
charcoal-stripped FBS was changed to cells 3 h before
transfection. For silencing of PIAS1, Dharmacon ON-
TARGETplus SMARTpool for human PIAS1 (siPIAS1)
(SMART pool of four individual siRNAs that were de-
signed to minimize off-target effects) and non-targeting
pool (siNON) were used at 100 nM final concentration us-
ing Trans-IT-siQUEST reagent (Mirus Bio Corp.) accord-
ing to the manufacturer´s instructions. After 96 h, cells were
exposed to vehicle (ethanol, EtOH) or androgen. For im-
munoblotting, RT-qPCR and Expression BeadChip analy-
ses, cells were exposed to testosterone (100 nM) for 16 h and
for proliferation assays to R1881 (10 nM) for 3 and 6 days.
For ChIP-seq, cells were transfected by reverse transfec-
tion with siNON or siPIAS1 at 40 nM concentration using
the Lipofectamine R© RNAiMAX reagent (Invitrogen) ac-
cording to the manufacturer´s instructions. VCaP cells were
seeded in growth medium onto six-well plates (500 000–600
000 cells/well) or 10-cmplates (5 000 000 cells/plate) forAR
and FOXA1 ChIP-seq, respectively. After 72 h, the medium
was changed to transfection medium for 48 h, and prior to
ChIP, the cells were exposed to R1881 (10 nM) for 2 h.
Immunoblotting and immunoprecipitation
VCaP cell samples were prepared as described (27) and
analyzed by immunoblotting with anti-PIAS1 (Santa-Cruz
Biotechnology, sc-8152), anti-AR (28), anti-p21 (Millipore,
OP64) and anti-tubulin (Santa-Cruz Biotechnology, sc-
5286) antibodies. The appropriate secondary antibody was
from Invitrogen and chemiluminescence detection reagents
from Pierce. PIAS1 was immunoprecipitated with anti-
PIAS1 antibody (Abcam, ab109388) which was coupled
to Magna ChIPTM Protein A Magnetic Beads (Millipore).
Normal rabbit IgG (Santa-Cruz Biotechnology, sc-2027)
was used as a control antibody and the immunoprecipitates
were immunoblotted with anti-AR (Santa-Cruz Biotech-
nology, sc-7305) antibody. For FOXA1 and PIAS1 im-
munoprecipitation, anti-FOXA1 (Abcam, ab23738) anti-
body was used to immunoprecipitate FOXA1 and the
immunoprecipitates were immunoblotted with anti-PIAS1
(Abcam, ab77231) antibody.
Reporter gene assays
VCaP cells were seeded onto 12-well plates (300 000
cells/well) for 2 days before transfection. The transfec-
tion medium DMEM containing 2.5% charcoal-stripped
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FBS was changed on cells 6 h before the cells were trans-
fected with 600 ng of pARE2-TATA-LUC (29), and 100
ng pCMV (Clontech), 100–300 ng pFlag-PIAS1 (20) or
pFlag-PIAS13CS. In the case of the latter plasmid, the three
cysteine residues C346, C351 and C356 in the mPIAS1
RING domain were mutated to serines by QuikChange
II Site-Directed Mutagenesis Kit (Stratagene) according
to the manufacturer’s instructions. Point mutations were
verified by sequencing. The total amount of DNA per
well was balanced at 1000 ng with empty pFlag-CMV-2
(Sigma-Aldrich) and X-tremeGENE HP DNA Transfec-
tion Reagent (Roche) was used according to the manufac-
turer´s instructions. Twenty-four hours after transfection,
cells were exposed to R1881 or vehicle for 17 h. Reporter
gene activity was measured as described (29).
RNA isolation, real-time quantitative PCR (RT-qPCR) and
microarray analysis
Total RNA in biological triplicates was extracted (TriPure
isolation reagent, Roche) and converted to cDNA (Tran-
scriptor First Strand cDNA synthesis Kit, Roche) accord-
ing to the manufacturer’s instructions. Expression of target
genes with specific primers (Supplementary Table S1) was
measured by RT-qPCR as described in (30) using GAPDH
mRNA levels to normalize the amounts of total RNA be-
tween the samples. Illumina HumanHT-12 v4 Expression
BeadChip analyses were carried out at the FinnishMicroar-
ray and Sequencing Centre (Turku, Finland) using proto-
cols recommended by the manufacturer. The data were an-
alyzed and visualized as described (31). The genes with ad-
justed P-value of <0.01 and fold change (FC) ≥1.5 and
≤0.7 were selected as significantly changed transcripts. To
identify biological processes enriched for differentially ex-
pressed genes, the data were analyzed through the use of
Ingenuity Pathway Analysis R© (IPA, www.ingenuity.com).
A core analysis was first performed with two distinct lists
(androgen-regulated genes in siNON- and siPIAS1-treated
cells) and the results were then compared to identify any dis-
tinct biological processes that were differentially regulated.
Cell proliferation assay
VCaP cells were grown and transfected with siNON and
siPIAS1 as described above. After 72 h, the cells were seeded
onto 96-well plates (5000 cells/well) in transfectionDMEM
containing 2.5% charcoal-stripped FBS. After 6 h, the cells
were exposed to vehicle or R1881 for 3 and 6 days. The
amount of viable cells was measured using CellTiter-Glo R©
Luminescent Cell Viability Assay (Promega) according to
the manufacturer´s instructions. The results were calculated
as percentage of cell growth using the first measurement
(day 0) as reference point (100%).
Chromatin immunoprecipitation (ChIP), re-ChIP and ChIP-
coupled to deep sequencing (ChIP-seq)
The protocol for ChIP experiments and analyses were per-
formed as described (30). Briefly, the cells were seeded onto
10-cm plates (3 000 000 cells/dish) and grown for 72 h
in growth medium. Steroid-depleted transfection medium
was changed 48 h before the cells were exposed to ve-
hicle or R1881 for 2 h. Cells were crosslinked with 1%
(v/v) formaldehyde and harvested for immunoprecipitation
with anti-AR (28), anti-PIAS1 (ab 77231), anti-FOXA1 (ab
23738), anti-H3K4me2 (ab 7766), anti-SUMO2/3 (MBL
International 114-3), anti-RNA polymerase II (Covance,
MMS-126R) or anti-IgG (sc-2027) antibody.Re-ChIP anal-
yses were performed essentially as described (32). Chro-
matin was sequentially precipitated with anti-PIAS1 (ab
77231) and anti-FOXA1 (ab 23738) antibodies. qPCR anal-
yses from chromatin templates were performed as described
(30). Specific primers for different genomic regions are
listed in Supplementary Table S2. Single-end AR (siNON),
PIAS1, FOXA1 and SUMO2/3 (androgen) ChIP-seq data
were generated using Solexa/Illumina 1.5 System in the
Biomedicum Functional Genomics Unit (Helsinki, Fin-
land) and AR (siPIAS1), FOXA1 (siNON and siPIAS1),
H3K4me2 and SUMO2/3 (vehicle) with HiSeq 2000 in
the EMBLGenomics Core Facility (Heidelberg, Germany).
Single-end ChIP-seq data for RNA polymerase II (Pol II)
were generated using Illumina 1.5 System in the BGI Tech
Solutions (Shenzhen, China). Raw read quality check, pre-
processing of reads (36-bp trimming) and Bowtie align-
ment were performed as described (31). Background (IgG)
read set was scaled that an individual background was gen-
erated for each AR, PIAS1 and FOXA1 ChIP-seq sam-
ple. The read ratio between IgG and ChIP-seq sample was
set to the same by randomly removing IgG reads the way
that the ratio became the same for each ChIP-seq sam-
ple. The scaled IgG and unscaled AR, PIAS1 and FOXA1
reads were converted to sorted sam files using SAM tool
(33). The same files were analyzed using HOMER software
version 4.1 (34). Enriched binding sites were detected us-
ing findPeaks command with factor analysis strategy us-
ing 4-fold enrichment over IgG background read set. We
sequenced single H3K4me2 sample and two independent
biological replicates per sample for AR, PIAS1, FOXA1,
SUMO2/3 and Pol II. Our biological replicates showed a
good concordance (summary table of the peaks used in Sup-
plementary Table S3). The samples met ENCODE guide-
lines; ≥10 million uniquely mapped reads per sample were
gained, control IgG sample sequence depth was at the level
of other ChIP-seq samples and replicate similarity matched
the guidelines (35,36). Overlapped binding sites between
each replicate pair were identified using BEDTools (37).
Binding sites found in both replicates and normalized tag
count ≥10 were used as final binding sites in analysis. To
analyze unique binding sites for two chromatin binders, the
non-overlapping binding sites were identified using getD-
ifferentialPeaks command of HOMER using 3-fold differ-
ence in the occupancy of the chromatin binders. HOMER
software was used as (31) to visualize data, for peak po-
sition annotation and for de novo motif analyses. Associa-
tion of binding sites to the nearby genes (±50 kb from tran-
scription start site, TSS) and androgen-regulated genes was
donewithAnduril as described (38).Genescoreswere calcu-
lated to nearby genes by taking into account the peak signal
strength (normalized tags), distance between TSS and the
peak and number of associated peaks to genes (with linear
scoring function).
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Accession numbers
Bead array and ChIP-seq data are submitted to the NCBI
Gene Expression Omnibus database (39) (http://www.ncbi.
nlm.nih.gov/geo/) and are accessible through GEO Series
accession numbers GSE30316 and GSE56086, respectively.
RESULTS
PIAS1 and AR interact in prostate cancer cells
Based on mRNA expression, PIAS1 is the major PIAS1
family member in VCaP cells and the only PIAS protein
whose mRNA expression is up-regulated by androgens (32)
(Supplementary Figure S1A). Co-immunoprecipitation as-
says (immunoblotting of anti-PIAS1 immunoprecipitates
with anti-AR antibody) confirmed the interaction between
endogenous PIAS1 and AR in VCaP cells (Supplementary
Figure S1B). Transfection of increasing doses of plasmids
encoding PIAS1 or PIAS1 SP-RINGmutant together with
a minimal AR-regulated-promoter driven reporter gene
(pARE2-TATA-LUC) further demonstrated that PIAS1
can influence the transcriptional activity of VCaP cell AR
in a fashion that is dependent on the intact PIAS SP-RING
structure (Supplementary Figure S1C).
PIAS1 activates or represses androgen-regulated genes in a
target gene-selective fashion
We next investigated the role of PIAS1 for the androgen-
regulated transcriptome in VCaP cells. PIAS1 was depleted
from the cells using transfected PIAS1-specific siRNAs
(siPIAS1) and cells transfected with non-targeting siRNAs
(siNON) were used as a control. PIAS1 depletion was con-
firmed by immunoblotting with anti-PIAS1 antibody (Fig-
ure 1A). Gene expression profiling of cells treated with an-
drogen or vehicle revealed that more genes were regulated
by androgen in PIAS1-depleted than in control siNON cells
(1 767 versus 1 341) (Figure 1B) (listed in Supplementary
file S1). Expression of ∼10% of the AR-regulated genes in
siNON cells (hereafter control cells) was significantly influ-
enced, either activated (FC ≥1.5) or repressed (FC ≤0.7),
by PIAS1 depletion. The majority of AR target genes in
control cells remained androgen-responsive also in PIAS1-
depleted cells, but ∼4% of the target genes lost their re-
sponse to androgen upon PIAS1 depletion (e.g.KLK2). No-
tably, PIAS1 depletion exposed a large set of new genes
(820) to androgen regulation, suggesting that PIAS1 can
mask genes, such as NR5A2, from AR access (Figure 1B)
(Supplementary file S1). The number of genes affected by
PIAS1 depletion in the absence of androgen (138, Supple-
mentary file S1) was much smaller than that in the presence
of androgen, implying that PIAS1 is relatively selective to
androgen-regulated genes in VCaP cells.
We next grouped all androgen-regulated genes with un-
supervised hierarchical clustering (Figure 1C). Genes that
were robustly up- or down-regulated by androgen, but
did not markedly differ in their expression between the
control and PIAS1-depleted cells were present in clus-
ters 1 (e.g. FKBP5) and 7 (e.g. AR). Clusters 2 and 3
contained genes that were androgen-up-regulated in both
control and PIAS1-depleted cells, but that had a differ-
ence in either fold-induction by androgen or both fold-
induction and overall expression level with androgen (e.g.
RASD1 and HPGD, respectively). Similarly, genes that
were androgen-down-regulated both in control and PIAS1-
depleted cells, but had a difference in their expression be-
tween the control and the PIAS1-depleted cells were clus-
tered to clusters 6 (e.g.CSRP2) and 8 (e.g. TMEFF2). Clus-
ters 4 and 5 were particularly interesting. Cluster 4 was en-
riched for genes that were up-regulated by androgen only in
PIAS1-depleted cells (e.g.NR5A2) and genes whose andro-
gen down-regulation was converted to up-regulation upon
PIAS1 depletion (e.g. ATAD2). Cluster 5, in turn, was en-
riched for genes that were androgen up-regulated only in
control cells (e.g. KLK2). In sum, these transcriptome pro-
files indicate that PIAS1 depletion affects, either activates or
represses, in a gene selective manner expression of number
of the androgen-regulated transcripts in VCaP cells. More-
over, a subset of genes becomes subject to androgen regula-
tion upon PIAS1 depletion.
PIAS1 affects prostate cancer cell proliferation
All androgen-regulated genes in PIAS1-depleted and con-
trol cells were next subjected to Ingenuity Pathway
Analysis R© (IPA) to identify enriched molecular and/or cel-
lular functions and pathways affected by PIAS1. Cellu-
lar growth and proliferation, cellular development, cellu-
lar movement, and cell cycle and cell survival were the
top five molecular and cellular functions significantly en-
riched in both PIAS1-depleted and control cells (Fig-
ure 1D). Canonical pathways of cholesterol biosynthe-
sis I–III and the superpathway of cholesterol biosynthe-
sis showed the most significant differences in their enrich-
ment between control and PIAS1-depleted cells, when all
androgen-regulated genes were analyzed (Supplementary
Figure S2A). In addition to these biosynthesis pathways,
PIAS1 is predicted to be involved in the regulation of cell
cycle-related events. Top canonical pathways enriched in
the interesting cluster 4 (Figure 1C; androgen up-regulated
only in PIAS1-depleted cells or androgen down-regulation
converted to up-regulation upon PIAS1 depletion) included
several signaling pathways, such as neuregulin, xenobiotic
metabolism, PTEN, G beta gamma and PI3K/AKT signal-
ing (Supplementary Figure S2B). In cluster 5 (genes andro-
gen up-regulated only in control cells), the enriched path-
ways were the superpathway of cholesterol biosynthesis and
purine nucleotides de novo biosynthesis II. The top five
molecular and cellular functions enriched among the group
of genes masked from androgen regulation by PIAS1 were
gene expression, protein synthesis, cell cycle, cancer and cell
death and survival (Figure 1E). An interaction map of the
genes annotated to the top twomolecular and cellular func-
tions, gene expression and the protein synthesis, is shown in
Supplementary Figure S3.
Since IPA analyses suggested involvement of PIAS1 in
the regulation of expression of genes governing cellular pro-
liferation and survival, we next studied the effect of PIAS1
depletion on cell growth. Cell growth assays indicated that
PIAS1 depletion results in attenuated growth of VCaP cells
both in the presence and absence of added androgen (Fig-
ure 2A). These results are in line with gene expression
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Figure 1. PIAS1 depletion affects androgen-regulated transcriptome of VCaP cells. VCaP cells were transfected with control siRNA (siNON) or PIAS1
siRNA (siPIAS1) and the cells were exposed to androgen (testosterone) or vehicle (ethanol) for 16 h, RNAs were isolated and microarray analysis was
performed. (A) PIAS1 and AR protein levels in PIAS1-depleted VCaP cells. Cell lysates were immunoblotted with indicated antibodies. (B) Venn diagram
showing androgen-regulated genes in siNON and siPIAS1 cells (1341 and 1767 genes, respectively). Green circle indicates AR-regulated genes significantly
affected by PIAS1 depletion (when comparing fold changes of androgen-regulated genes in siNON- and siPIAS1-treated cells). (C) Heat map of the
normalized expression values of differentially expressed transcripts in the BeadChip arrays based on unsupervised hierarchical clustering. (D) Biological
processes of androgen-regulated transcripts in siNON and siPIAS1 cells as revealed by Ingenuity pathway analysis. Numbers in parentheses indicate the
amount of transcripts linked to each biological process and percentages their relative portions among the androgen-regulated genes. Benjamini–Hochberg
(B–H) multiple testing correlation was used for enrichment analysis. (E) Biological processes of the genes masked from androgen regulation by PIAS1 (820
genes) as revealed by IPA. B-H multiple testing correlation was used for enrichment analysis.
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Figure 2. PIAS1 influences proliferation of VCaP cells. (A) VCaP cells were transfected with siNON (control) or siPIAS1 and cells were exposed to
androgen or vehicle and cell numbers were measured by CellTiter96 Aqueous cell proliferation assay as described in ‘Materials and Methods’ section.
Growth percentages represent the means of three independent experiments ± SDs. (B) Effect of PIAS1 depletion on the expression of select AR target
genes linked to cell growth and apoptosis. Cells were treated as in Figure 1, but RNA quantification was carried out by RT-qPCR with specific primers for
BCL6, ATAD2, NR5A2, MAGEH1, CLDN8, MAFB, TNFSF10, CSRP2, IGFBP-3 and TMEFF2 mRNAs. Measurements were normalized to GAPDH
mRNA levels, and fold changes were calculated in reference to siNON and vehicle samples. Data points indicate the means of at least three biological
replicates ± SDs. Student’s t test was used to determine the significance of fold change differences between siNON and siPIAS1 cells when comparing
androgen- and vehicle-exposure (***P < 0.001, **P < 0.01 and *P < 0.05).
data showing that BCL6 (cluster 4), ATAD2 (cluster 4),
NR5A2 (cluster 4), MAGEH1 (cluster 4), CLDN8 (cluster
5), MAFB (cluster 6), TNFSF10 (cluster 6), CSRP2 (clus-
ter 6), IGFBP-3 (cluster 7) and TMEFF2 (cluster 8) that
are androgen-regulated genes associated with cell growth
and apoptosis or cancer (40–48) (Supplementary Figure S4)
were significantly affected by PIAS1 depletion (Figure 2B).
Androgen-enhanced co-occupancy of PIAS1 and AR on chro-
matin
To complement the above analyses, we next investigated
whether PIAS1 is able to bind chromatin and interact with
AR also on VCaP cell chromatin. Genome-wide ChIP-
seq analysis was performed also for AR in androgen-
treated cells. Comparison of recently reported VCaP cell
AR cistromes (7,8) with our AR data identifying 41 469
AR-binding sites (ARBs), showed a good (>70%) over-
lap with the ARBs in all data sets (Supplementary Figure
S5). Interestingly, PIAS1 ChIP-seq revealed 3904 PIAS1-
binding sites that overlapped almost completely (>97%)
with the ARBs (Figure 3A and B). Of note, the ARBs
with the strongest signals were the ones enriched at PIAS1-
occupying sites, as illustrated with the correlation of AR
versus PIAS1 tag signals of within the ARBs (Figure 3C).
ChIP-seq of H3K4me2, a mark of active enhancers and
chromatin, showed similar enrichment adjacent to both
AR/PIAS1-shared and AR sites (Figure 3B). In addi-
tion, RNA polymerase II (Pol II) at promoter regions and
two other active enhancer/promoter marks, H3K4me3 and
acetylated H3 (panH3ac) (data from GEO), were also en-
riched at AR/PIAS1-shared genomic regions, further sup-
porting the notion that these genomic regions are transcrip-
tionally potent regions (Supplementary Figure S6). The
overall distribution of AR and AR/PIAS1-shared sites to
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Figure 3. ChIP-seq analysis of AR- and PIAS1-binding sites on VCaP cell chromatin. (A) Venn diagram showing overlap of AR and PIAS1 cistromes in
cells exposed to androgen (10 nM R1881) for 2 h (upper panel). Heat map showing AR- and PIAS1-binding site tag densities in ±2 kb window (lower
panel). (B) Comparison of AR, PIAS1 andH3K4me2 average tag counts in±500 bp from the centers of AR- and PIAS1-binding sites in unique ARBs and
AR/PIAS1-shared sites. (C) Scatter plot of AR and PIAS1 tag signals around ±500 bp of the AR/PIAS1-shared binding sites. (D) Venn diagram showing
overlap of PIAS1 cistromes in presence and absence of androgen (upper panel). Non-overlapping sites were further analyzed using get-DifferentialPeak
tool to achieve final categories. Heat map showing PIAS1-binding site tag densities for vehicle/androgen-shared and unique androgen regions in a window
±2 kb (lower panel). (E) Comparison of PIAS1 and H3K4me2 average tag counts in±500 bp from the centers of PIAS1-binding sites in vehicle/androgen-
shared and androgen unique sites.
gene structures was very similar, mostly in intergenic and
intronic in both cases (Supplementary Figure S7A).
The majority (>70%) of the androgen-regulated genes
in both control and PIAS1-depeleted cells had at least one
ARB and ≥25% of the genes had at least one AR/PIAS1-
shared-binding site within±50 kb of their TSS (Supplemen-
tary Figure S7B). To further analyze association of genes to
the nearby peaks, a gene score that takes into account the
peak signal strength (normalized tags), distance between
the peak and TSS and number of associated peaks was
calculated for each gene. Both the ARBs and AR/PIAS1-
shared sites showed stronger association with androgen-
regulated genes than with non-regulated genes, with the
AR/PIAS1-shared sites showing higher gene scores than
the AR sites (Supplementary Figure S7C). PIAS1 depletion
did not, however, alter the gene scores.
Comparison of the PIAS1 cistrome in VCaP cells in the
presence of androgen to that in the absence of the hormone
revealed that androgen exposure increased the number
of PIAS1-occupying chromatin sites >4-fold (Figure 3D),
with about half (45%) of the sites in vehicle-exposed cells
overlapping with those in androgen-treated cells. Based on
tag densities of PIAS1 occupancy and average tag profiles,
the majority of PIAS1-binding sites (67%) were considered
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Figure 4. Androgen enhances PIAS1-binding to ARE motif-containing
chromatin sites. (A) The top four motifs predicted by de novo motif anal-
ysis of all PIAS1-binding sites. De novo motif analysis was performed on
±100 bp of the PIAS1 (vehicle and R1881 sites) peak center. (B) Distribu-
tion of the most enriched de novo motifs in vehicle/androgen-shared and
androgen unique sites. Statistical significances were calculated by χ2-test
(***P < 0.001 and **P < 0.01).
unique to androgen exposure, i.e. they showed at least 3-
fold difference (FC> 3) between the occupancy in the pres-
ence and absence of androgen (Figure 3D). Genomic lo-
cation analyses showed that PIAS1 binds by and large to
intronic and intergenic regions irrespectively of androgen
treatment (Supplementary Figure S8A). H3K4me2 marks
showed somewhat stronger enrichment in the surroundings
of vehicle/androgen-shared than androgen unique PIAS1
sites (Figure 3E).
PIAS1 interacts with FOXA1 and SUMO2/3 on chromatin
We next performed de novo motif analyses of all PIAS1-
binding sites to identify transcription factor-binding motifs
enriched within them. Interestingly, FOXA1 motif was the
most enriched motif in both vehicle/androgen-shared and
androgen unique sites (Figure 4A). Approximately 70% of
the PIAS1 sites shared by vehicle- and androgen-exposed
cells showed a FOXA1 motif and <30% of them had an
ARE, whereas both a FOXA1 and an ARE motif were
found at about the same frequency (∼50% and ∼55%, re-
spectively) in the PIAS1 sites unique to androgen expo-
sure (Figure 4B). At least one ARE and FOXA1 motif
occurred together ∼1.5-times more frequently in the an-
drogen unique sites (41%) than in the vehicle/androgen-
shared sites (28%). Comparison of the average tag counts in
±300 bp from the centers of PIAS1 peaks further showed a
higher occurrence of FOXA1 motifs at the summits of the
vehicle/androgen-shared sites than at those of the androgen
exposure unique sites (Supplementary Figure S8B). Also
NKX3.1 and GATA motifs were enriched in the PIAS1-
occupying chromatin sites, with the GATA motifs being
clearly more prevalent in the vehicle/androgen-shared sites
than androgen unique sites (Figure 4B).
The above ChIP-seq data suggest that PIAS1 inter-
acts with FOXA1. Co-immunoprecipitation assays (im-
munoblotting of anti-FOXA1-immunoprecipitates with
anti-PIAS1 antibody) confirmed the interaction of the two
proteins in VCaP cells (Figure 5A). These data prompted
us to map the FOXA1 cistrome in VCaP cells and relate
it to the PIAS1 cistrome. We identified 58 364 and 69 780
FOXA1-binding sites in vehicle- and androgen-treated cells,
respectively (Figure 5B). Compared to PIAS1, the effect of
androgen on the formation of new FOXA1 chromatin bind-
ing sites wasminor (plus 20%), albeit the hormone generally
enhanced FOXA1′s chromatin binding events on the sites
co-occupied by the AR (Figure 5B). Interestingly, the over-
lap of PIAS1 with FOXA1 in the presence and absence of
androgen was nearly complete, being in both cases ≥93%
(Figure 5C). Practically all PIAS1-binding sites overlapped
with both FOXA1 and AR in androgen-exposed cells (Fig-
ure 5D). To investigate whether PIAS1 and FOXA1 are
directly interacting on chromatin, we utilized re-ChIP as-
says. Chromatin was sequentially immunoprecipitated with
anti-PIAS1 and anti-FOXA1 antibody and analyzed using
qPCR with primers for selected genomic regions exhibit-
ing (based on ChIP-seq data) co-occupancy of PIAS1 and
FOXA1 (ATAD2 and FKBP5) or only FOXA1 occupancy
(S100P) (Supplementary Figure S9). These experiments
confirmed simultaneous presence of PIAS1 and FOXA1 at
ATAD2 and FKBP5 regions, but not at the S100P region,
thus providing further proof for a direct interaction between
PIAS1 and FOXA1 proteins on chromatin.
We also performed ChIP-seq analyses with anti-
SUMO2/3 antibody in the presence and absence of
androgen. In keeping with the role of PIAS1 as a SUMOy-
lation pathway component, PIAS1, AR, and FOXA1
co-occurring genomic sites were also generally bound by
SUMO2/3 and the binding of SUMO2/3 was markedly
enhanced by androgen exposure (Figure 6). Figure 7 shows
snapshots of MAFB, ATAD2, CLDN8, RASD1, BCL6,
and IGFBP-3 loci as examples of chromatin co-occupancy
of AR and PIAS1 together with FOXA1 and SUMO2/3.
Their androgen-regulated expression is significantly af-
fected by PIAS1 depletion (cf.Figure 2). Except forATAD2
and BCL6, PIAS1 or FOXA1 binding was not detected
in the co-occupying chromatin regions prior to androgen
exposure.
Influence of PIAS1 on AR and FOXA1 chromatin occupancy
FOXA1 depletion has been shown to elicit extensive redis-
tribution of ARBs on prostate cancer cell chromatin (7).
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Figure 5. Interaction of PIAS1 with FOXA1. (A) PIAS1 and AR co-immunoprecipitate with FOXA1. VCaP cells exposed to vehicle (−) or androgen
(+, R1881) for 2 h were immunoprecipitated with anti-FOXA1 antibody or normal rabbit IgG (used as a control antibody). The immunoprecipitates and
the input cell lysates were analyzed by immunoblotting with indicated antibodies. (B–D) ChIP-seq analyses of FOXA1-, PIAS1- and AR-binding sites in
VCaP cells. (B) Venn diagram showing overlap of FOXA1 cistromes after vehicle and androgen exposure (2 h) and heat map showing FOXA1, AR and
H3K4me2-binding site tag densities in a window ±2 kb (−, vehicle; +, androgen exposure). (C) Venn diagrams showing overlap of FOXA1- and PIAS1-
binding sites in vehicle- and androgen-exposed cells. (D) Venn diagram showing overlap of AR-binding sites with FOXA1- and PIAS1-binding sites in
androgen-exposed cells.
Also PIAS1 depletion influenced the number of ARBs, al-
beit most of the AR cistrome remained unaffected (Fig-
ure 8A). Based on ARB tag densities and average tag pro-
files in siNON- and siPIAS1-treated cells (Figure 8A and
B), PIAS1 depletion resulted in emergence of nearly three
thousand (2 772) new ARBs, and a concomitant loss of less
than thousand (1 067) sites. Even though the average signals
of these binding events, especially the PIAS1-dependent
ones, were generally weaker than those of the PIAS1 level-
unaffected ones, they were reproducible and seen in both
replicates. Snapshots of ten loci displaying these binding
events are shown as examples in Supplementary Figure
S10. Interestingly, de novo motif analyses of the unaffected
and affected sites revealed that the new ARBs contained
more often HOXD13 andGATAmotifs, but less frequently
AREs, than the PIAS1 depletion insensitive sites or the sites
from which AR binding was lost (Figure 8C and D). The
new ARBs on chromatin did not however generally over-
lap with the PIAS1 or FOXA1 cistromes (Supplementary
Figure S11). The effect of PIAS1 depletion on the FOXA1-
occupying chromatin sites was smaller than that on the AR
cistrome: less than one thousand (906) newFOXA1 sites ap-
peared and a negligible number of sites (28) were lost (Sup-
plementary Figure S12A). According to de novomotif anal-
yses, the new FOXA1-binding sites harbored less frequently
FOXA1 and HOXD13 motifs, but more often AREs than
the PIAS1 depletion insensitive sites (Supplementary Fig-
ure S12). These results suggest that in addition to interact-
ing with AR and FOXA1 on chromatin, PIAS1 can indi-
rectly regulate chromatin occupancy of AR or FOXA1, but
this does not seem to be its main mechanism of action.
DISCUSSION
Androgen-regulated gene programs require in addition to
androgen, the AR and RNA polymerase II machinery, a
number coregulator proteins, coactivators and corepressor
(1). Expression patterns of coregulator proteins are thought
to underlie tissue-specific differences in AR-regulated gene
programs. Deregulated expression of AR coregulators has
been, in turn, suggested to contribute to CRPC (49). PIAS1
is one of the putative AR coregulators overexpressed in clin-
ical prostate cancer samples (23,24), albeit its expression
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Figure 6. Androgen-enhanced co-occurrence of SUMO2/3 at AR-,
PIAS1- and FOXA1-shared genomic locations. Venn diagram showing the
overlap of FOXA1, AR, and PIAS1 cistromes in cells exposed to andro-
gen (upper panel).Heatmap showing SUMO2/3 tag densities for indicated
Venn sectors in a window ±2 kb (−, vehicle; +, androgen exposure) (mid-
dle panel). Comparison of SUMO2/3 average tag counts in ±500 bp from
the centers of the indicated sites (lower panel).
appears to be lower in hormone-refractory prostate tumors
than in untreated prostate tumors (50). In this work, we
have employed unbiased approaches to reveal the genome-
wide role of PIAS1 in the regulation of AR target gene ex-
pression in VCaP cell line. Silencing of PIAS1 in VCaP cells
affected expression of AR target genes. However, it did not
have a general repressing or activating effect on all AR tar-
gets, but PIAS1 depletion resulted in significant activation
or repression of about one tenth of all genes. This implies
that the ability of PIAS1 to regulate AR target genes is in-
triguingly target-specific, and that it exhibits characteristics
of both a coactivator and a corepressor.
According to the pathway analyses of all androgen-
regulated genes in control vs. PIAS1-depleted cells, PIAS1
is involved in the regulation of canonical pathways of
cholesterol biosynthesis which potentially supports intra-
tumoral androgen biosynthesis enhanced in CRPC (5,6).
Gene expression analyses also indicated that PIAS1 can
mask a large group of genes, such as NR5A2, VLDLR
andCAMK1, from androgen regulation. Themost enriched
molecular and cellular functions among the latter gene
group were gene expression, protein synthesis, cell cycle,
cancer, cell death and survival. In keeping with the role of
PIAS1 in cell cycle and growth, silencing of PIAS1 atten-
uated growth of VCaP cells, also in the absence of added
androgen. Our results are in agreement with two recent
studies utilizing both AR negative and positive cell lines
(23,51). According to Hoefer et al. (23), PIAS1 depletion
increased the proportion of cells in the GO/G1 phase and
decreases the portion in the S-phase, which they reported
in AR negative PC3 cells to be mediated by increased p21
protein levels. In VCaP cells, the silencing did not how-
ever result in up-regulation, but slight down-regulation,
of p21 mRNA accumulation (Supplementary Figure S13),
suggesting that the mechanism underlying the attenuated
cell growth is more complex. Interestingly, many AR tar-
gets that are linked to cell growth and apoptosis, such as
ATAD2,BCL6,MAFB,TNFSF10 (TRAIL), IGFBP-3, and
TMEFF2 were regulated by PIAS1 (41–48). TMEFF2 has
previously been shown exhibit antiproliferative effects in
prostate cancer cells. ATAD2 andMAFB are interesting ex-
amples of AR target genes whose androgen-mediated re-
pression was converted to activation upon PIAS1 deple-
tion in VCaP cells. ATAD2 has previously been implicated
as a coactivator for AR in prostate cancer (44) and for c-
MYC in many aggressive tumors (52). Both ATAD2 and
MYC are overexpressed in prostate tumors and their expres-
sion is critical for prostate cell proliferation and survival.
TNFSF10 and IGFBP-3 are androgen-repressed genes with
pro-apoptotic effects (43,47). In VCaP cells, PIAS1 attenu-
ated their expression especially in the absence of androgens.
PIAS1 was able to bind to chromatin, mainly at FOXA1
motif-containing sites in the absence of added androgen,
but androgen exposure increased the number of PIAS1-
binding sites markedly, resulting in practically complete
overlap with about one tenth of the AR cistrome. PIAS1
sites resulting from the androgen exposure showed enrich-
ment for AREs and FOXA1 motifs at about the same fre-
quency of 50%. In general, the ARBs with the strongest sig-
nals were co-enriched with the PIAS1-binding chromatin
sites, andmore than one fourth of the genes regulated by an-
drogen were associated with relatively nearby (± 50 kb from
their TSSs) AR/PIAS1-shared sites. The AR- and PIAS1-
shared sites were proximal to an active enhancer mark of
H3K4me2, implying their active involvement in transcrip-
tional regulation. The PIAS1 cistrome also showed almost
complete overlap with the FOXA1 cistrome, but again,
<10% FOXA1 binding sites was shared with PIAS1. These
data are in line with our gene expression data revealing AR
target gene selective action of PIAS1. The genes associated
with cell growth, apoptosis and cancer listed in the previ-
ous paragraph are prominent examples of AR-, PIAS1- and
FOXA1-co-occupied enhancers.
Recent comparison of steroid receptor coactivator 3
(SRC-3) cistrome to estrogen receptor (ER)  and FOXA1
cistromes in breast cancer cells revealed that estrogen in-
creases only modestly (∼30%) the co-occupancy of the
coactivator with the receptor or FOXA1 and that only 30%
of the SRC-3 cistrome overlaps with the ER and FOXA1
cistromes (53). In comparison to the situation of SRC-3,
the overlap of the PIAS1 cistrome with the AR and the
FOXA1 cistromes is rather remarkable, suggesting that the
PIAS1 actively recruited to the AR target gene-regulating
enhancers. This is likely to occur via complex formation
of PIAS1 with both holo-AR and FOXA1 either prior to
or after chromatin binding of the latter two factors. PIAS1
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Figure 7. ChIP-seq track examples of AR-, PIAS1-, FOXA1- and SUMO2/3-binding events in growth-associated AR target loci in VCaP cells. The
occupancy of AR (dark blue in siNON-treated cells and light blue in siPIAS1-treated cells) and H3K4me2 (violet) in the presence of androgen (+, R1881
2 h) and that of PIAS1 (green), FOXA1 (purple) and SUMO2/3 (red) in the absence (−) and presence (+) of androgen. Red bars below the tracks depict
the positions of the identified peak sites and red arrows sites co-occupied by AR, PIAS1, FOXA1 and SUMO2/3. Except for IGFBP-1, the expression of
all loci was affected by androgen exposure.
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Figure 8. Influence of PIAS1 depletion on the AR cistrome. VCaP cells were treated as in Figure 7. (A) Venn diagram showing overlap of AR cistromes in
siNON and siPIAS1 cells (upper panel). Non-overlapping sites were further analyzed using get-DifferentialPeak tool to achieve final categories. Heat map
showing AR tag densities for siNON unique, siNON/siPIAS1-shared and siPIAS1 unique sites in a window ±2 kb (lower panel). (B) Comparison of AR
and H3K4me2 average tag counts in ±500 bp from the centers of the shared and unique sites. (C) The four most enriched motifs of AR-binding sites in
VCaP cells. Initial de novo motif discovery was performed on all AR-binding sites (siNON) on ±100 bp of the peak center. (D) Distribution of the most
enriched de novo motifs in siNON unique, siNON/siPIAS1-shared and siPIAS1 unique sites. Statistical significances were calculated by χ2-test (***P <
0.001).
has been also suggested to be capable of binding on its own
to DNA via its amino terminal scaffold attachment factor-
A/B, acinus and PIAS (SAP) domain (22).
In comparison to FOXA1 depletion which elicits exten-
sive redistribution of ARBs on prostate cancer cell chro-
matin (7), PIAS1 depletion had only relatively small effects
on AR chromatin occupancy. The new ARBs uncovered
by PIAS1 depletion harbored more often HOXD13 and
GATA motifs than the other AR-binding sites. Interest-
ingly, the homeodomain protein HOXB13 that recognizes
the HOXD13 motif has been shown to interact with AR
and behave as a bifunctional regulator of AR transcrip-
tional activity, showing characteristics of both a coactiva-
tor and corepressor (54). Moreover, germline mutations in
HOXB13 are associated with a significantly increased risk
of hereditary prostate cancer (14). Since the new ARBs did
not however generally overlap with the PIAS1 cistrome,
it is possible that PIAS1 is regulating SUMOylation of
HOXD13 and GATA factors, but this is likely to take place
off-chromatin.
In line with the interaction of FOXA1 with PIAS1 as
a SUMOylation pathway component, we have recently
shown that FOXA1 is SUMOylated and that the mod-
ification modulates its activity and interaction with AR
(55). Given that SUMO2/3 co-occurred with PIAS1 at
FOXA1- and AR-binding enhancer sites, we propose in our
schematic model (Figure 9) that the regulatory effects of
PIAS1 at these genomic loci are, at least in part, mediated
via enhanced SUMOylation of FOXA1 and/orARor other
factors, which influences their interactions with coregulator
proteins. In conclusion, our genome-wide analyses strongly
suggest that PIAS1 functions as a genuine and chromatin-
bound AR coregulator and that it cooperates with the pi-
oneer factor FOXA1 in an AR target gene selective fash-
ion to regulate gene programs relevant to prostate cancer
cell growth and signaling. Further studies are required to
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Figure 9. A schematic model of PIAS1 function on AR target genes regu-
lating prostate cancer cell growth. Androgen-bound ARs recruit PIAS1 to
chromatin enhancer sites that are neighbored by FOXA1 and surrounded
by active chromatin H3 methyl marks. PIAS1 subsequently promotes
SUMO2/3 (S2/3) modification of FOXA1 and/or AR and other factors,
which also influences interactions with coregulator proteins (CoR). Pol II;
RNA polymerase II and basal transcription machinery.
decipher the role of PIAS1′s SUMO ligase function on chro-
matin and assess whether PIAS1 could be utilized as a ther-
apeutic target for inhibition of prostate cancer cell growth.
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